SYMPOSIUM 2009
CARDIO SYMPOSIUM 2009
About the event
First Human and Veterinary Crossover Symposium on Aldosterone
The contribution of aldosterone to heart failure was the focus of a recent symposium, hosted by Ceva Santé Animale. The principle of this symposium was to promote expertise exchanges between human and veterinary medicine. The programme included eminent cardiology researchers from around the world, both from the human and veterinary fields.
You will find in this report a summary of the presentations and the discussions that took place, mixing state of the art science with the most recent clinical developments in man and animals.
We hope that you will both enjoy and benefit from the research compiled herein.
Sylvie Bourrelier and Emilie Guillot
Corporate Marketing – Veterinary Technical Support
Ceva Santé Animale
Feedback on event
100% of attendees thought this concept of Crossover Symposium interesting / very interesting (69%).
87% expressed an overall satisfied / very satisfied impression about the scientific session.
97% had a satisfied / very satisfied overall impression of the Symposium.
Regarding the global organisation 95% of the participants were satisfied / very satisfied and 97% enjoyed the social program.
Sessions
Aldosterone and mineralocortoid receptors: expanding views from the kidney to the cardiovascular system.
- Nicolette Farman
Overexpression of the mineralocorticoid receptors: pathophysiological consequences
- FRÉDÉRIC JAISSER
Mineralocorticoid receptor blockade: how experimental evidence supports the clinical benefit
- Johann Bauersachs
The proximate cause of heart failure: models, remodeling, and re-remodeling
- Robert Hamlin
Efficacy of spironolactone in dogs with naturally occurring Myxomatous Mitral Valve Disease. (part I)
- Claudio Bussadori
Efficacy of spironolactone in dogs with naturally occurring Myxomatous Mitral Valve Disease. (part II)
- Claudio Bussadori
Principles of survival analysis illustrated by CEVA’s spironolactone trials
- Martin Bland
Current clinical status and future directions for biomarkers in heart failure
- FAIEZ ZANNAD
